宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展

doi:10.19803/j.1672-8629.20230620

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (1): 55-58.
DOI: 10.19803/j.1672-8629.20230620

• 呼吸道病毒性疾病与中医药防治机制研究专栏 • 上一篇下一篇

宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展

张敬升¹, 冀祖恩^2,3△, 庞博¹, 徐英莉¹, 曹姗¹, 张宇¹, 孙绮悦¹, 孙静¹, 李舒冉¹, 张薇^2,3, 赵荣华^1,*, 崔晓兰^1#

¹中国中医科学院中药研究所, 北京 100700;
²新疆甘草及制品研究重点实验室, 新疆库尔勒 841011;
³新疆全安药业股份有限公司, 新疆库尔勒 841011

收稿日期:2023-09-28 出版日期:2024-01-15 发布日期:2024-01-18
通讯作者: ^*赵荣华,女,副研究员,中药药效作用机制研究。E-mail：zhaoronghua203@163.com; ^#为共同通信作者。
作者简介:张敬升,男,在读博士,中药抗感染药理研究。^Δ为并列第一作者。
基金资助:
国家重点研发计划（2021YFC1712903）; 中国中医科学院科技创新工程（C12021A04606）

Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection

ZHANG Jingsheng¹, JI Zuen^2,3△, PANG Bo¹, XU Yingli¹, CAO Shan¹, ZHANG Yu¹, SUN Qiyue¹, SUN Jing¹, LI Shuran¹, ZHANG Wei^2,3, ZHAO Ronghua^1,*, CUI Xiaolan^1#

¹Institute of Chinese Materia Medica, China Academy of Chinese MedicalSciences, Beijing 100700, China;
²Xinjiang Key Laboratory for Research of Licorice and Products, Korla Xinjiang 841011, China;
³Xinjiang Quanan Pharmaceutical Co., Ltd., Korla Xinjiang 841011, China

Received:2023-09-28 Online:2024-01-15 Published:2024-01-18

摘要/Abstract

摘要： 目的探讨宣肺败毒方治疗新型冠状病毒感染的中医学理论,归纳该方的药理实验研究进展,为扩展该方的临床应用和进一步的实验研究提供参考。方法采用理论研究与文献调研相结合的方法,探讨宣肺败毒方的中医学理论和药理学进展,归纳该方的实验研究。结果宣肺败毒方适用于湿毒郁肺的患者,宣肺败毒方可通过PD-1/IL17A、IL-6/STAT3及CXCL2/CXCR2等通路改善肺损伤,以及NF-κB通路减轻肠道疾病。结论宣肺败毒方是中药和科技结合的产物,既有充分的中医药理论支撑,亦有足够的现代药理实验研究证据支持。

关键词: 宣肺败毒方, 新型冠状病毒感染, 湿毒郁肺, 中医学, 药理

Abstract: Objective To discuss the traditional Chinese medicine (TCM) theory of Xuanfei Baidu decoction in treating novel coronavirus infection, summarize the experimental study of this prescription, and provide reference for later clinical and experimental purposes. Methods Using the methods of theoretical research and literature investigation, this paper discusses and summarizes the TCM theory of Xuanfei Baidu decoction and summarizes the experimental study. Results Xuanfei Baidu decoction is suitable for patients with dampness-toxic stagnation of lung. And the PD-1/IL17A, IL-6/STAT3 and CXCL2/CXCR2 pathways were used to ameliorate lung injury and NF-κB pathway to alleviate intestinal diseases. Conclusion Xuanfei Baidu decoction is a combination of TCM and science and technology, which is supported by both TCM theory and modern experimental research evidence.

Key words: Xuanfei Baidu decoction, Coronavirus Disease 2019（COVID-19）, lung with dampness-toxic stagnation, traditional Chinese medicine, pharmacology

中图分类号:

张敬升, 冀祖恩, 庞博, 徐英莉, 曹姗, 张宇, 孙绮悦, 孙静, 李舒冉, 张薇, 赵荣华, 崔晓兰. 宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展[J]. 中国药物警戒, 2024, 21(1): 55-58.

ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan. Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230620

https://www.zgywjj.com/CN/Y2024/V21/I1/55

参考文献

[1] General Office of National Health Commission of the People’s Republic of China. General Comprehensive Affairs Department of National Administration of Traditional Chinese Medicine of the People’s Republic of China. Novel coronavirus infection prevention and control consensus and treatment of novel coronavirus(10th trial edition)[J]. China Medicine(中国医药), 2023, 18(2): 161-166.
[2] WANG Y,LI X,ZHANG JH, et al.Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(10): 2249-2256.
[3] ZHOU L, WANG XN, LIU XK, et al.Case report of Xuanfei Baidu decoction for curing severe cases of COVID-2019[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2021, 38(5): 556-559.
[4] XIE M.The logical proposition of“prescription and proof correlation”and its significance[J]. Journal of Beijing University of TCM(北京中医药大学学报), 2003(2): 11-12.
[5] XIE M,ZHOU R.Formulaology(方剂学)[M]. Beijing: People’s Medical Publishing House, 2012.
[6] Anongmous. Inner Canonof Yellow Emperor Volume of 21(黄帝内经二十一卷)[M]. Beijing: People’s Medical Publishing House, 2005.
[7] WU YK. Wen Yi Lun(瘟疫论)[M]. Beijing: People’s Medical Publishing House, 2007.
[8] General Office of National Health Commission of the People’s Republicof China,Office of National Administration of Traditional Chinese Medicine.Diagnosis and treatment of corona virus disease-19(7th trial edition)[J]. China Medicine(中国医药), 2020, 15(6): 801-805.
[9] General Office of National Health Commission of the People’s Republic of China. Guidelines on diagnosis and treatment of novel coronavirus pneumonia(trial version 3)[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2020, 37(1): 1-3.
[10] HONG BJ, CHEN XT.Distribution of TCM syndrome elements and regularity of prescription and drug use in traditional Chinese medicine diagnosis and treatment schemes for corona virus disease 2019[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志),2020, 47(3): 109-112.
[11] ZHAI XJ, LI YH, MENG FF,et al.Analysis of COVID-19 based on the opening and closing angle of Huangdi Neijing[J]. Asia-Pacific Traditional Medicine, 2022, 18(8): 200-203.
[12] YANG HS,WANG L,JIANG LD.JIANG Liangduo’s understanding on novel coronavirus disease from“Qi Failing to Control Fluid”[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(7): 561-563, 593.
[13] GU XH.Discussion on etiology, pathogenesis and principles of differentiation and treatment of COVID-19 based on the Traditional Chinese Medicine Diagnosis and Treatment Plan for COVID-19 of Beijing(the Seventh Trial Edition)[J]. Modern Chinese Clinical Medicine, 2023, 30(4): 1-5.
[14] WU T.Wen Bing Tiao Bian(温病条辨)[M]. Beijing: People’s Medical Publishing House, 1972.
[15] LIU ZL,SHI LQ,MA JL,et al.Discussion of traditional Chinese medicine syndrome and treatment of novel coronavirus pneumonia based on pulmonary spleen-related pathogenesis[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2020, 37(4): 377-382.
[16] HE MY. Yi Bian(医碥)[M]. Beijing: People’s Medical Publishing House, 1994.
[17] LI DY. Pi Wei Lun(脾胃论)[M]. Beijing: People’s Medical Publishing House, 2005.
[18] XIE M.Thoughts on the prescription formulating and application of qingfei paidu decoction in traditional Chinese medicine for the preventing and treating coronavirus disease 2019[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(13): 1105-1109.
[19] Chinese Pharmacopoeia Commission.Pharmacopoeia of People’s Republic of China[S]. Beijing:China Medical Science Press, 2015.
[20] PANG WT,ZHANG LS,YANG FW,et al.Discussion on method of opening with pungent drugs and descending with bitter drugs in treatment of corona virus disease[J]. Chinese Archives of Traditional Chinese Medicine, 2020, 38(3): 7-9.
[21] TAO HJ.Ming Yi Bie Lu(名医别录)[M]. Beijing: People’s Medical Publishing House, 1986.
[22] LI SZ.Ben Cao Gang Mu(本草纲目)[M]. Beijing: Traditional Chinese Medicine Ancient Books Publishing House, 1994.
[23] ZHANG L.Ben Jing Feng Yuan(本经逢原)[M]. Beijing: Traditional Chinese Medicine Ancient Books Publishing House, 2017.
[24] PANG WT, YANG FW, ZHENG WK, et al.Clinical efficacy evaluation of Xuanfei Baidu granule in the treatment of omicron virus infection with COVID-19[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2022, 39(9): 1093-1098.
[25] FENG LM,LIU XY,ZHANG L.Clinical observation of Xuanfei Baidu granule in the treatment of COVID-19(Omicron)[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2022, 39(5): 545-550.
[26] BI YF,MA ZR,YANG XD, et al.Two cases of severe patients with novel coronavirus pneumonia were treated with Xuanfei Baidu decoction[J]. Journal of Traditional Chinese Medicine(中医杂志), 2022, 63(2): 198-200.
[27] XUE YJ, QU B, SHAO R, et al.Network pharmacology analysis on mechanisms of Xuanfei Baidu Prescription intreatment of SARS, MERS and COVID-19[J]. Drugs & Clinic(现代药物与临床), 2021, 36(12): 2473-2487.
[28] WANG Y, WANG X, LI Y, et al.Xuanfei Baidu Decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathways[J]. Pharmacol Re, 2022, 176: 106083.
[29] WANG Y, SANG X, SHAO R, et al.Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway[J]. J Ethnopharmacol, 2022, 283: 114701.
[30] MA L, ZHAO X, LIU T, et al.Xuanfei Baidu Decoction attenuates intestinal disorders by modulating NF-κB pathway, regulating T cell immunity and improving intestinal flora[J]. Phytomedicine, 2022, 101: 154100.
[31] LI C, LI Y, ZHANG H, et al.Xuanfei Baidu Decoction suppresses complement overactivation and ameliorates IgG immune complex-induced acute lung injury by inhibiting JAK2/STAT3/SOCS3 and NF-κB signaling pathway[J]. Phytomedicine, 2023, 109: 154551.
[32] YAN H, LU J, WANG J, et al.Prevention of cyclophosphamide-induced immunosuppression in mice with traditional Chinese medicine Xuanfei Baidu decoction[J]. Front Pharmacol, 2021, 12: 730567.
[33] ZHOU M, LIU Y, QIN H, et al.Xuanfei Baidu decoction regulates NETs formation via CXCL2/CXCR2 signaling pathway that is involved in acute lung injury[J]. Biomed Pharmacother, 2023, 161: 114530.

宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展

Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李心蕾, 贡磊磊, 王晓霞, 张雪艳, 赵涵, 姚伟洁, 袁偲偲, 冯欣. 基于网络药理学和分子对接探讨养血安胎颗粒治疗复发性流产分子作用机制[J]. 中国药物警戒, 2024, 21(4): 366-370.
[2]	茹尘, 侯秀娟, 钱唐亮, 杜梦梦, 李媛, 刘小平, 朱跃兰. 中药复方治疗干燥综合征的配伍规律及作用机制研究[J]. 中国药物警戒, 2024, 21(4): 397-403.
[3]	顾晓彤, 孙雪林, 郑丽. 治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展[J]. 中国药物警戒, 2024, 21(4): 469-472.
[4]	马丽娜, 胡晓祯, 郑长辉, 孙颖, 赵旭, 曹俊岭, 肖小河. 基于“因毒为能”思想的有毒中药常山毒效转化知识图谱可视化分析[J]. 中国药物警戒, 2024, 21(1): 25-32.
[5]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[6]	杨珍珍, 常成, 高娜, 张晓林, 宋银森, 刘颖, 范天黎. 基于网络药理学和体外研究探讨木犀草素抑制食管鳞状细胞癌的分子机制[J]. 中国药物警戒, 2023, 20(9): 992-1001.
[7]	李婧, 徐烨, 刘冉佳, 潘晨, 崔向丽. 新型冠状病毒感染患者使用托珠单抗后发生不良反应的病例分析[J]. 中国药物警戒, 2023, 20(9): 1049-1053.
[8]	殷玉玲, 胡楚涓, 张晓朦, 王雨, 张冰, 林志健. 菊苣提取物抗阿霉素心脏毒性作用挖掘及验证[J]. 中国药物警戒, 2023, 20(8): 858-865.
[9]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.
[10]	地力乎马·地力木拉提, 石伟, 王伽伯, 高源. 基于毒/效记载演变探讨补骨脂的安全应用研究进展[J]. 中国药物警戒, 2023, 20(8): 939-945.
[11]	苏月芬, 郑婧柔, 宫贺, 谢广通, 张洁, 赛春梅. 乳腺结重痛轻凝胶贴膏的成型性及治疗乳腺增生作用机制研究[J]. 中国药物警戒, 2023, 20(7): 783-790.
[12]	陈梦苹, 王雅欣, 姚荣妹, 包蕾, 赵荣华, 孙静, 耿子涵, 鲍岩岩, 戴敏, 郭姗姗, 崔晓兰. 基于网络药理学及实验验证探究清开灵软胶囊治疗冠状病毒肺炎的作用机制[J]. 中国药物警戒, 2023, 20(3): 253-257.
[13]	蔡于罗, 果佳慧, 王鑫国, 田义龙, 王梦, 牛丽颖, 李军山. 彝族药蜘蛛香的研究进展及质量标志物的预测分析[J]. 中国药物警戒, 2023, 20(3): 348-352.
[14]	付昌丽, 陆苑, 陈思颖, 王永林, 李勇军, 王爱民, 刘春花. 红禾麻入血成分治疗类风湿性关节炎的作用机制[J]. 中国药物警戒, 2023, 20(2): 171-176.
[15]	王晓慧, 张帆, 夏文彬, 魏玉辉. 基于网络药理学和转录组学探讨京尼平致肝毒性机制[J]. 中国药物警戒, 2023, 20(2): 177-180.